+++
date = '2025-10-05'
draft = false
title = 'Damage_symptoms'
+++
Muscle Damage–Associated Symptoms in LGMDR2 / Miyoshi Myopathy (MM)
LGMDR2 (Limb-Girdle Muscular Dystrophy R2) and Miyoshi Myopathy (MM) belong to the spectrum of Dysferlinopathies, which are caused by mutations in the DYSF gene encoding the dysferlin protein. Dysferlin plays a critical role in sarcolemmal repair and vesicle fusion during muscle membrane resealing. Its loss leads to chronic muscle damage, inflammation, and progressive weakness.
1. Overview of Muscle Damage–Associated Symptoms

<table style="border-collapse:collapse;width:115%;">
    <colgroup>
    <col style="width:15%;">
    <col style="width:30%;">
    <col style="width:30%;">
    <col style="width:25%;">
  </colgroup>
  <thead>
    <tr>
      <th style="text-align:center;border:1px solid #ddd;padding:8px;">Category</th>
      <th style="text-align:center;border:1px solid #ddd;padding:8px;">Specific Symptoms</th>
      <th style="text-align:center;border:1px solid #ddd;padding:8px;">Mechanism</th>
      <th style="text-align:center;border:1px solid #ddd;padding:8px;">Comparison with Normal Muscle Damage</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:center;border:1px solid #ddd;padding:8px;">Progressive muscle weakness</td>
      <td style="text-align:left;border:1px solid #ddd;padding:8px;">Loss of proximal (LGMDR2) or distal (MM) strength; difficulty climbing stairs, running, or tiptoeing</td>
      <td style="text-align:left;border:1px solid #ddd;padding:8px;">Chronic fiber necrosis and incomplete regeneration; fatty/fibrotic replacement</td>
      <td style="text-align:left;border:1px solid #ddd;padding:8px;">Similar to loss of functional capacity but chronic and irreversible</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Progressive muscle weakness</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Loss of proximal (LGMDR2) or distal (MM) strength; difficulty climbing stairs, running, or tiptoeing</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Chronic fiber necrosis and incomplete regeneration; fatty/fibrotic replacement</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Similar to loss of functional capacity but chronic and irreversible</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Chronic hyperCKemia</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Persistent elevation of serum CK (often &gt;5000&nbsp;IU/L)</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Continuous membrane leakage and cytoplasmic protein release</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Unlike transient CK rise post-exercise, persists long-term</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Myalgia / tenderness</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Muscle pain and tenderness, worsened after exertion</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Accumulation of microdamage and release of proinflammatory cytokines (IL-6, TNF-α)</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Resembles DOMS but continuous</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Muscle swelling / pseudohypertrophy</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Apparent calf enlargement with weakness</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Inflammatory edema and fat infiltration</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Similar to edema-induced swelling</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Muscle atrophy</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Visible muscle volume reduction in calves, quadriceps</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Chronic fiber loss and atrophy</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Final stage of structural degeneration</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Inflammatory cell infiltration</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Macrophage and CD8+ T cell infiltration in biopsy</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Chronic sterile inflammation due to membrane rupture</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Persistent vs transient inflammatory phase</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Exercise-induced exacerbation</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Symptoms worsen after activity; CK spikes</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Repair defect causes cumulative damage</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Recovery delayed or incomplete</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Muscle protein leakage</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Leakage of CK, myoglobin, LDH, aldolase into blood</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Sarcolemmal repair failure</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Persistent leakage vs transient rise</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Cycles of necrosis–regeneration</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Muscle fibers with central nuclei</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Repetitive injury-regeneration cycles</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Reflects chronic degeneration</td>
    </tr>
    <tr>
        <td style="text-align:center;border:1px solid #ddd;padding:8px;">Functional limitations</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Fatigue, gait difficulty, limited movement</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Loss of strength and coordination</td>
        <td style="text-align:left;border:1px solid #ddd;padding:8px;">Chronic form of reduced capacity</td>
    </tr>
</tbody>
</table>

1. Laboratory and Imaging Indicators
- Blood: CK↑, LDH↑, AST/ALT mildly elevated → ongoing muscle injury
- Muscle biopsy: absent dysferlin staining, necrosis–regeneration cycles, inflammatory infiltration
- MRI: early posterior leg muscle fat replacement, T2 hyperintensity (edema/inflammation)
- EMG: myopathic pattern (low amplitude, short duration potentials)

1. Mechanistic Comparison
Normal exercise-induced damage: reversible membrane disruption, transient CK elevation, inflammation resolving in days.
Dysferlinopathy-related damage: defective membrane repair → persistent leakage, inflammation, and fibrosis.

1. Summary
In LGMDR2/MM, muscle damage–associated symptoms represent a chronic form of injury combining structural disruption, biochemical leakage, inflammation, and progressive degeneration. These processes resemble normal post-exercise muscle damage but fail to resolve due to the absence of functional dysferlin-mediated sarcolemmal repair.
